| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Are there safety concerns for biosimilars?
|
Lekkerkerker, Frits
|
|
2009
|
21 |
1-2 |
p. 47-52
|
artikel
|
| 2 |
Biologicals
|
van Boxtel, Chris J.
|
|
2009
|
21 |
1-2 |
p. 1-3
|
artikel
|
| 3 |
Biologicals in Japan
|
Hama, Rokuro
|
|
2009
|
21 |
1-2 |
p. 59-68
|
artikel
|
| 4 |
Biopharmaceuticals in the Russian Federation: A snapshot of policies for registration, reimbursement and use
|
Ziganshina, Lilia E.
|
|
2009
|
21 |
1-2 |
p. 75-88
|
artikel
|
| 5 |
Biosimilar medicines and safety: New challenges for pharmacovigilance
|
Rägo, Lembit
|
|
2009
|
21 |
1-2 |
p. 5-11
|
artikel
|
| 6 |
Biosimilars: The French policy
|
Schück, Stéphane
|
|
2009
|
21 |
1-2 |
p. 41-45
|
artikel
|
| 7 |
Homicidal ideation causally related to therapeutic medications
|
Marks, Donald H.
|
|
2009
|
21 |
1-2 |
p. 119
|
artikel
|
| 8 |
How the European Union reviews and approves ‘follow-on biologics’ or biosimilar products
|
Rossignol, Nicolas
|
|
2009
|
21 |
1-2 |
p. 105-109
|
artikel
|
| 9 |
IMS Health reports global biotech sales grew 12.5 percent in 2007, exceeding $75 billionIMS news releases
|
|
|
2009
|
21 |
1-2 |
p. 111-113
|
artikel
|
| 10 |
Overview of safety monitoring of biologicals in China
|
Chen, Yixin
|
|
2008
|
21 |
1-2 |
p. 69-74
|
artikel
|
| 11 |
Pharmacovigilance of biosimilars from a regulatory point of view: Is there a need for a specific approach?
|
Giezen, Thijs J.
|
|
2009
|
21 |
1-2 |
p. 53-58
|
artikel
|
| 12 |
Quality and safety considerations for recombinant biological medicines: A regulatory perspective
|
Barnes, Henry J.
|
|
2009
|
21 |
1-2 |
p. 13-22
|
artikel
|
| 13 |
Sandoz receives European Commission approval for biosimilar filgrastimNovartis Media releases
|
|
|
2009
|
21 |
1-2 |
p. 117
|
artikel
|
| 14 |
Tainted blood in Canada: An extraordinary history
|
Dukes, M.N. Graham
|
|
2009
|
21 |
1-2 |
p. 89-92
|
artikel
|
| 15 |
The global biopharma industry and the rise of Indian drug multinationals: Implications for Australian generics policy
|
Löfgren, Hans
|
|
2009
|
21 |
1-2 |
p. 31-40
|
artikel
|
| 16 |
The Heparin Story
|
Usdin, Steve
|
|
2009
|
21 |
1-2 |
p. 93-103
|
artikel
|
| 17 |
UK biotech seeks bail out
|
|
|
2009
|
21 |
1-2 |
p. 115-116
|
artikel
|
| 18 |
Vaccine policy, regulations and safety in India
|
Gogtay, N.J.
|
|
2009
|
21 |
1-2 |
p. 23-30
|
artikel
|
Tijdschrift beschrijving